It's the industry's biggest turnout in the Super Bowl in three years.
PhRMA and BIO ramp up ad spend for presidential election year; Super Bowl Sunday features three pharma ads; Pfizer solidifies leadership team
The awards have four new categories: Best Use of Relationship Marketing, Best Use of Data/Analytics, Best Film or Video, and Most Daring Campaign.
The drugmaker's CEO said the campaign helps dispel pessimism created from a history of cancer drugs that lack "significant value."
This message will be clear: catch up to the email channel. Now.
Many of the characters we are now meeting do not appear to be directed at a patient insight or purposefully used to de-stigmatize a disease.
Campaigns around opioid abuse, lung cancer drugs and women's health took the spotlight in 2015.
Drug pricing is easily the biggest controversy but pharma faced other issues, too, like the AMA's call to ban DTC advertising.
The drugmaker's lead product, Rasuvo, is an injectable version of a commonly prescribed drug used to treat rheumatoid arthritis.
Jaimy Lee talks with Sudler & Hennessey's Rob Rogers, 2015 Lions Health pharma jury president, about what made this campaign worthy of a trophy, and what the win says about the ongoing debate about creativity versus conservatism in pharma advertising.
The campaign marks the drugmaker's foray into oncology DTC advertising as it vies for market share against competing treatment Keytruda.
A powerful opportunity has emerged to publish content directly on LinkedIn in order to increase the visibility of a company's corporate narrative and services as part of an integrated marketing strategy that spans paid, owned and earned media.
The company plans to run the campaign through 2016 to counteract slowing sales for Tecfidera.
The drugmaker aims to differentiate its type-2 diabetes drug in the competitive GLP-1 receptor agonist class.
From clinical trials to customer planning, digital can speed the biopharma product launch at each step, said Nancy Phelan, BMS head of commercial operations, at last week's MM&M Leadership Exchange.
The drugmakers worked with Evoke Health to develop a campaign that would differentiate the third-in-class type-2 diabetes drug in an increasingly competitive market.
The drugmaker launched its first YouTube channel as it kicked off the campaign.
The drugmaker's marketing teams will likely lean on its dosing profile to gain an edge in the crowded diabetes market.
In order to reach consumers, hospitals must rethink their old ways of marketing outreach.
Are warning letters—and the corrective ads they spur—enough to ensure marketers get it right the first time?
GSK awards its global media buying business; one-third of patients dropped out of Xenoport psoriasis trial; an experimental drug for liver disease fails to meet primary endpoints
We're not out to reinvent the wheel if we don't have to but we will need to localize the campaign for New Zealand and do what is right for our physicians and our patients.
Sandoz plans to take a branded approach as it launches the first FDA-approved biosimilar product.
Contrary to popular belief, Addyi is not the female Viagra. That's the message drug-maker Sprout must get across to doctors and patients in the coming weeks.
Sprout plans to hire 200 sales reps, targeting 30,000 doctors, to accompany the drug's launch.
Allergan executives attributed strong sales of branded products to recent investments in direct-to-consumer advertising.
The drugmaker, which sells prostate-cancer treatment Xtandi, wants social-media users to help spread the word about the disease
The "Surprise, it's insulin" campaign follows criticism of the lower-than-expected sales of the inhaled insulin since its launch in February.
Pfizer, through the Better Business Bureau's National Advertising Division, disputes that Novartis's Theraflu 'starts to work in the body in 5 minutes.'
Arena's recent quarter shows weight-loss drug Belviq is on the rise. It follows a DTC push and the recent addition of reps by co-marketer Eisai.